NCT02959658View on ClinicalTrials.gov

Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 21, 2019

Study Completion Date

December 9, 2020

Conditions

Primary Progressive Multiple Sclerosis

Interventions

DRUG

Dimethyl fumarate

DRUG

Placebo

Manufactured to mimic Dimethyl Fumarate capsules

Trial Locations (1)

2100

Danish Multiple Sclerosis Center, Department of neurology, Copenhagen

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Biogen

INDUSTRY

lead

Rigshospitalet, Denmark

OTHER